Page 0014

GLOBAL CANCER INITIATIVES

14 CANCER CONTROL 2021

interests are prevention, preventive strategies, social inequalities,

antimicrobial resistance and a whole of society approach to public

health. She is an intensive care nurse by education.

Jon Kirknes is Head of Department for Cancer Research and

Prevention at the Norwegian Cancer Society. Previously he headed

the section for cancer care. He has wide experience in political

advocacy, organizational development and leadership. Jon is also

board member at Gemini Centre for Sepsis Research.

Anna Zorzet has a PhD in Medical Microbiology with a focus on

antibiotic resistance from Uppsala University. She has been working

for the global network ReAct - Action on Antibiotic Resistance since

2011. She was Director of ReAct Europe for 7 years and now serves

as a strategic adviser. Anna is also a member of the UICC Task Force

on AMR.

sustainable supply of medicines and diagnostics (existing and

new) for cancer patients, especially in LMICs.

Against this background a more in-depth discussion on

access to antimicrobials for cancer patients will take place

during the forthcoming 3rd LGCW in November 2021. The

focus of this session will be access to medicines and diagnostics.

Taking forward the messages from LGCW 2020, speakers at

this session will elaborate on and provide insight into possible

partnerships in ensuring equitable access to treatments

globally. The session is once again a partnership between UICC,

the Wellcome Trust, the Norwegian Cancer Society and will

include UICC task force members, SIOP and ReAct along with

insights from the industry. n

Research areas that need urgent attention and

collaboration

J Strengthening surveillance capacity to ensure quality data

on the impact of AMR.

J Evidence generation on the impact of AMR on cancer care

outcomes.

J Evidence-based resources to increase knowledge and

awareness on AMR across communities to influence policy

change.

J Ensuring equitable access to novel therapies.

Shalini Jayasekar Zürn is a senior advocacy manager with the

Union for International Cancer Control (UICC). She is a biologist

by training and has extensive experience on the issues of access to

quality-assured medicines. Shalini gained experience in this topic

by working with the World Health Organization on their Model List

of Essential Medicines as well as Médecins Sans Frontières's access

campaign and other NGOs. She also has experience working with

the pharmaceutical industry.

Sonali Johnson is Head of Knowledge, Advocacy and Policy at

the Union for International Cancer Control (UICC). Her main area

of work is to ensure that cancer prevention, treatment, and care

is positioned within the global health and development agenda,

including plans for universal health coverage (UHC). During her

professional career, Sonali has worked on a range of public health

issues including cancer control, gender and HIV/AIDS, reproductive

and sexual health, gender based violence, knowledge translation,

research ethics and health and human rights.

Sonali holds a PhD and post-doctorate diploma in public health

and policy from the London School of Hygiene and Tropical Medicine

and an MSc in Gender and Development from the London School of

Economics and Political Science.

Carina Alm is a special adviser at the Norwegian Cancer Society

working in the field of noncommunicable diseases (NCDs). Her special

Index

  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038
  39. Page 0039
  40. Page 0040
  41. Page 0041
  42. Page 0042
  43. Page 0043
  44. Page 0044
  45. Page 0045
  46. Page 0046
  47. Page 0047
  48. Page 0048
  49. Page 0049
  50. Page 0050
  51. Page 0051
  52. Page 0052
  53. Page 0053
  54. Page 0054
  55. Page 0055
  56. Page 0056
  57. Page 0057
  58. Page 0058
  59. Page 0059
  60. Page 0060
  61. Page 0061
  62. Page 0062
  63. Page 0063
  64. Page 0064
  65. Page 0065
  66. Page 0066